Fig. 5: Safety and treatment exposures. | Nature Communications

Fig. 5: Safety and treatment exposures.

From: Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial

Fig. 5

a Most frequent treatment-related adverse events (frequency >5%) in the safety population throughout the study period on the left in red (n = 74) and during the maintenance phase with glasdegib monotherapy on the right in yellow (n = 28). b Treatment duration in the overall population and in patients who discontinued treatment due to toxicity. Each dot represents a patient, and the blue areas along the x axis are proportional to the number of patients with that treatment duration. The gray box plot represents the median and 25–75% interquartile range. The horizontal lines represent 95% CIs. Data is shown for the full dataset for any reason (n = 74 patients) and for the subgroup of 13 patients who discontinued due to toxicity (n = 13). c Pharmacokinetic profile of glasdegib after a course of 14 days of oral administration of 75 mg/day glasdegib in concomitance with 5 mg/m2/day TMZ and 1.8-2 Gy/day RT. The blue line represents the median, and the gray bars represent the standard error for each time point (n = 8 patients).

Back to article page